---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-25-000079"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2025-11-07T23:59:59+00:00"
generated_at: "2026-05-16T22:58:59.570473+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling

## Summary
- Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.
- R&D expense $2.7M (net of $1.7M Théa reimbursement) vs $2.1M in Q3 2024.
- Q3 2025 net income $27K vs net loss of $3.4M in Q3 2024, driven by tax impacts and noncash gains.
- Both Phase 2 trials — KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa) — continue recruitment and dosing.
- Received $1.2M in reimbursed R&D from Théa in Q3; billed an additional $1.5M in the quarter.

## SEC filing metadata
- accession: 0001372514-25-000079
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2025-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000079/0001372514-25-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251425000079/kprx-20251107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-25-000079
- JSON: https://secwatch.observer/filing/0001372514-25-000079.json
- Plain text: https://secwatch.observer/filing/0001372514-25-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.